Developer docs
API playgroundTry for free, no card

Search company profiles

BioEclipse Therapeutics

Full company profile

uuid0000pi3

Namestring
BioEclipse Therapeutics
Legal namestring
BioEclipse Therapeutics
Websiteurl
bioeclipse.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

BioEclipse Therapeutics is a clinical-stage biopharmaceutical company developing immuno-oncology therapeutics for patients with therapy-refractory solid tumors. Founded in 2006 as ConcentRx and rebranded in 2016, the company is headquartered in Mountain View, California, and operates from the Open Medicine Institute Collaboratory. Its pipeline centers on a proprietary platform that pairs cytokine-induced killer (CIK) cells with an oncolytic vaccinia virus, an architecture licensed exclusively from Stanford University and supported by preclinical data showing an approximately 1000-fold increase in cytotoxicity versus the individual components.

The lead asset, CRX100, is an autologous, intravenously administered combination currently in Phase 1b clinical trials for advanced solid tumors including ovarian, triple-negative breast, colorectal, hepatocellular carcinoma, osteosarcoma, and gastric cancers. A second asset, CRX200, is an allogeneic, off-the-shelf version of the platform positioned as IND-ready, intended to eliminate patient apheresis, reduce cell dose, and lower infusion burden. Clinical execution is concentrated at Moores Cancer Center (UC San Diego Health) and HonorHealth Research Institute (Scottsdale, AZ), with Stanford Women's Cancer Center's Oliver Dorigo serving as principal investigator on related work.

BioEclipse has no commercial products and is pre-revenue. Its economics will ultimately derive from pharmaceutical product sales following regulatory approval, supplemented by potential out-licensing or partnership transactions with larger pharmaceutical companies. To date it has raised approximately $9.3 million in equity through a June 2019 Series A-1 led by Revelis Capital Group and was awarded an approximately $8 million grant from the California Institute for Regenerative Medicine in April 2022. The company is led by CEO and co-founder Pamela Contag, Ph.D., whose prior company Xenogen was taken public, with a board that includes executives directly connected to the first FDA-approved cellular immunotherapy (Provenge/Dendreon).

Short descriptiontext

BioEclipse Therapeutics is a clinical-stage biopharmaceutical company developing autologous (CRX100, Phase 1b) and allogeneic (CRX200, IND-ready) immuno-oncology therapies that combine cytokine-induced killer cells with an oncolytic virus to treat therapy-refractory solid tumors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMountain View, United States
HQ citystring
Mountain View
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer immunotherapy, oncolytic virus therapy, solid tumor treatment, cell-based therapeutics, immuno-oncology platform
Industry2 codes
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Biopharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1None currently - Pre-revenue clinical stage
TypeOne Time License
Description

BioEclipse Therapeutics is a clinical-stage biopharmaceutical company that is not yet generating revenue. The company is focused on developing its lead immunotherapy candidate CRX100 through Phase 1 clinical trials. Future revenue generation would come from pharmaceutical product sales following regulatory approval or from licensing/partnership agreements with larger pharmaceutical companies.

bioeclipse.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

BioEclipse Therapeutics is a clinical-stage biopharmaceutical company that develops first-in-class, multi-mechanistic immuno-oncology therapeutics combining cytokine-induced killer (CIK) cells with an oncolytic virus to treat solid tumors. Its lead candidates are CRX100 (autologous, currently in Phase 1b clinical trials) and CRX200 (allogeneic, IND-ready), built on cell-therapy technology originally licensed from Stanford University.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 1 trial results showed stable disease in 1 patient with initial dose of 1E8 PFUs vaccinia plus 2-5E9 NK-T cells; 5 of 7 patients alive at 1-36 months post-treatment
+2 more records
Product overview1 text field

BioEclipse Therapeutics is a clinical-stage oncology company with a proprietary platform combining oncolytic virus technology with immune cell therapy. The company's portfolio consists of two immunotherapy products: CRX100 (autologous, Phase 1b), which combines cytokine-induced killer cells with an oncolytic virus and is being evaluated for treatment-resistant solid tumors; and CRX200 (allogeneic, IND ready), an off-the-shelf version offering superior manufacturing and administration advantages. Both products leverage a multi-mechanistic approach that activates innate immunity while generating adaptive immune responses against tumors.

Product and service2 records
1CRX100
CategoryCancer Immunotherapy
Description

Autologous multi-mechanistic immunotherapy candidate that combines cytokine-induced killer (CIK) cells with an oncolytic virus to treat solid tumors; currently in Phase 1b clinical trials. Targeted at oncology patients via clinical investigators at academic medical centers.

2CRX200
CategoryCancer Immunotherapy
Description

Next-generation allogeneic cell-based immunotherapy designed to remove the requirement for patient apheresis, enabling off-the-shelf treatment of solid tumors; currently IND-ready. Targeted at oncology patients and licensing partners.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeTechnology or Integration
Description

Technology exclusively licensed from Stanford University. CRX100 developed using patented Stanford technology. Clinical trial led by Principal Investigator Oliver Dorigo, MD, PhD from Stanford Women's Cancer Center.

2Moores Cancer Center at UC San Diego Health
Strategic tierCoreTypeStrategic or Co-development Partner
Description

First clinical trial site for Phase 1 dose-escalation trial of CRX100. Located in La Jolla, CA. Principal Investigator Sandip Patel, MD serves as Associate Professor at UC San Diego School of Medicine.

bioeclipse.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial site in Scottsdale, Arizona for Phase 1 dose-escalation trial. Principal Investigator Jasgit Sachdev, MD is Director of Breast and Gynecological Early Phase Clinical Trials at HonorHealth.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Professional services firm assisting biopharma companies with development and launch of new products. Worked with BioEclipse to complete IND filing and prepare for Phase 1 clinical trial.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Investor relations and media relations firm serving as contact for BioEclipse press inquiries. Provides communications support for corporate announcements.

6Mahmoud Mahmoudian
Strategic tierCoreTypeOthers
Description

Appointed to BioEclipse Board of Directors in January 2022. Brings 30+ years of biopharma experience from Sumitomo Dainippon Pharma Oncology, Merck, and GlaxoSmithKline. Led $70M in capital to build academic and venture hubs at Sumitomo Oncology.

bioeclipse.com
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Managing Director Stephen Ghiglieri serves as interim CFO for BioEclipse. Provides CFO services to life sciences companies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

BioEclipse was resident company at JLABS in South San Francisco from August 2017 to February 2020. Premier life science incubator program that provided expertise, connections, and team energy to help company grow to clinical-stage.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Targovax
TypeEmerging player
Description

Clinical-stage immuno-oncology company developing oncolytic virus (ONCOS-102) for solid tumors. Shares BioEclipse's oncolytic virus approach but is at earlier/mid clinical stage.

TypeDirect peer
Description

Clinical-stage oncology company developing a portfolio of oncolytic virus therapies (RP1, RP2, RP3) for solid tumors. Shares BioEclipse's oncolytic virus mechanistic approach but is at later clinical stage.

3Turnstone Biologics
TypeDirect peer
Description

Clinical-stage biotech developing oncolytic virus immunotherapies combined with cell therapy for solid tumors—directly analogous mechanism to BioEclipse's CRX100/CRX200 platform and the most head-to-head comparable peer.

TypeDirect peer
Description

Clinical-stage cell therapy company developing allogeneic CAR-T and NK cell therapies for solid tumors. Overlaps with BioEclipse on allogeneic cell therapy positioning for solid tumor indications.

TypeBroad incumbent
Description

Clinical-stage cell therapy company developing off-the-shelf, iPSC-derived NK and T-cell therapies for cancer. Comparable to BioEclipse's CRX200 allogeneic, off-the-shelf positioning with broader pipeline scale.

TypeDirect peer
Description

Cell therapy company developing engineered TCR-T therapies for solid tumors, with Tecelra FDA-approved for synovial sarcoma. Direct competitor in the cell therapy for solid tumors category.

TypeBroad incumbent
Description

Leading allogeneic CAR-T developer with substantially greater capital and clinical pipeline. Comparable on allogeneic cell therapy platform positioning but focused primarily on hematologic malignancies.

TypeDirect peer
Description

Leader in tumor-infiltrating lymphocyte (TIL) cell therapy for solid tumors, including the FDA-approved Lifileucel. Competes directly with BioEclipse in autologous cell therapy for refractory solid tumors.

TypeDirect peer
Description

Clinical-stage gene therapy and oncolytic virus company developing combination approaches for solid tumors, including cell therapy + oncolytic virus strategies that overlap with BioEclipse's platform.

TypeDirect peer
Description

Clinical-stage biotech developing oncolytic virus platforms (e.g., Voyager-V1) for solid tumor treatment. Directly comparable viral immunotherapy mechanism to BioEclipse's vaccinia virus component.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioEclipse Therapeutics

Oncology Biopharmaceuticalsbioeclipse.com

BioEclipse Therapeutics is a clinical-stage biopharmaceutical company developing autologous (CRX100, Phase 1b) and allogeneic (CRX200, IND-ready) immuno-oncology therapies that combine cytokine-induced killer cells with an oncolytic virus to treat therapy-refractory solid tumors.

What BioEclipse Therapeutics does

BioEclipse Therapeutics is a clinical-stage biopharmaceutical company developing immuno-oncology therapeutics for patients with therapy-refractory solid tumors. Founded in 2006 as ConcentRx and rebranded in 2016, the company is headquartered in Mountain View, California, and operates from the Open Medicine Institute Collaboratory. Its pipeline centers on a proprietary platform that pairs cytokine-induced killer (CIK) cells with an oncolytic vaccinia virus, an architecture licensed exclusively from Stanford University and supported by preclinical data showing an approximately 1000-fold increase in cytotoxicity versus the individual components.

The lead asset, CRX100, is an autologous, intravenously administered combination currently in Phase 1b clinical trials for advanced solid tumors including ovarian, triple-negative breast, colorectal, hepatocellular carcinoma, osteosarcoma, and gastric cancers. A second asset, CRX200, is an allogeneic, off-the-shelf version of the platform positioned as IND-ready, intended to eliminate patient apheresis, reduce cell dose, and lower infusion burden. Clinical execution is concentrated at Moores Cancer Center (UC San Diego Health) and HonorHealth Research Institute (Scottsdale, AZ), with Stanford Women's Cancer Center's Oliver Dorigo serving as principal investigator on related work.

BioEclipse has no commercial products and is pre-revenue. Its economics will ultimately derive from pharmaceutical product sales following regulatory approval, supplemented by potential out-licensing or partnership transactions with larger pharmaceutical companies. To date it has raised approximately $9.3 million in equity through a June 2019 Series A-1 led by Revelis Capital Group and was awarded an approximately $8 million grant from the California Institute for Regenerative Medicine in April 2022. The company is led by CEO and co-founder Pamela Contag, Ph.D., whose prior company Xenogen was taken public, with a board that includes executives directly connected to the first FDA-approved cellular immunotherapy (Provenge/Dendreon).

BioEclipse Therapeutics firmographics

Firmographics
Name
BioEclipse Therapeutics
Legal name
BioEclipse Therapeutics
Website
https://bioeclipse.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
1–10 employees
Short description
BioEclipse Therapeutics is a clinical-stage biopharmaceutical company developing autologous (CRX100, Phase 1b) and allogeneic (CRX200, IND-ready) immuno-oncology therapies that combine cytokine-induced killer cells with an oncolytic virus to treat therapy-refractory solid tumors.
Ownership category
akta.pro rank

BioEclipse Therapeutics industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Cancer immunotherapy
  • Oncolytic virus therapy
  • Solid tumor treatment
  • Cell-based therapeutics
  • Immuno-oncology platform

Where BioEclipse Therapeutics is headquartered

Location

Headquarters

HQ city
Mountain View
HQ country
United States
HQ region
North America

Offices1 record

Markets served

BioEclipse Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. None currently - Pre-revenue clinical stage: BioEclipse Therapeutics is a clinical-stage biopharmaceutical company that is not yet generating revenue. The company is focused on developing its lead immunotherapy candidate CRX100 through Phase 1 clinical trials. Future revenue generation would come from pharmaceutical product sales following regulatory approval or from licensing/partnership agreements with larger pharmaceutical companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

BioEclipse Therapeutics product offering

Product offering

Core offering

BioEclipse Therapeutics is a clinical-stage biopharmaceutical company that develops first-in-class, multi-mechanistic immuno-oncology therapeutics combining cytokine-induced killer (CIK) cells with an oncolytic virus to treat solid tumors. Its lead candidates are CRX100 (autologous, currently in Phase 1b clinical trials) and CRX200 (allogeneic, IND-ready), built on cell-therapy technology originally licensed from Stanford University.

Product overview

BioEclipse Therapeutics is a clinical-stage oncology company with a proprietary platform combining oncolytic virus technology with immune cell therapy. The company's portfolio consists of two immunotherapy products: CRX100 (autologous, Phase 1b), which combines cytokine-induced killer cells with an oncolytic virus and is being evaluated for treatment-resistant solid tumors; and CRX200 (allogeneic, IND ready), an off-the-shelf version offering superior manufacturing and administration advantages. Both products leverage a multi-mechanistic approach that activates innate immunity while generating adaptive immune responses against tumors.

Differentiator

Problem solved

Functional benefit

Products and services

  • CRX100 Autologous multi-mechanistic immunotherapy candidate that combines cytokine-induced killer (CIK) cells with an oncolytic virus to treat solid tumors; currently in Phase 1b clinical trials. Targeted at oncology patients via clinical investigators at academic medical centers.
  • CRX200 Next-generation allogeneic cell-based immunotherapy designed to remove the requirement for patient apheresis, enabling off-the-shelf treatment of solid tumors; currently IND-ready. Targeted at oncology patients and licensing partners.

Quantifiable outcome

  • Phase 1 trial results showed stable disease in 1 patient with initial dose of 1E8 PFUs vaccinia plus 2-5E9 NK-T cells; 5 of 7 patients alive at 1-36 months post-treatment
  • +2 more outcomes

Companies that use BioEclipse Therapeutics

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

BioEclipse Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

BioEclipse Therapeutics partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core.

  • Stanford UniversitycoreTechnology or IntegrationTechnology exclusively licensed from Stanford University. CRX100 developed using patented Stanford technology. Clinical trial led by Principal Investigator Oliver Dorigo, MD, PhD from Stanford Women's Cancer Center.
  • Moores Cancer Center at UC San Diego HealthcoreStrategic or Co-development PartnerFirst clinical trial site for Phase 1 dose-escalation trial of CRX100. Located in La Jolla, CA. Principal Investigator Sandip Patel, MD serves as Associate Professor at UC San Diego School of Medicine.
  • HonorHealth Research InstitutecoreStrategic or Co-development PartnerClinical trial site in Scottsdale, Arizona for Phase 1 dose-escalation trial. Principal Investigator Jasgit Sachdev, MD is Director of Breast and Gynecological Early Phase Clinical Trials at HonorHealth.
  • Spannerwerks, LLCcoreImplementation/ SI/ Consulting PartnerProfessional services firm assisting biopharma companies with development and launch of new products. Worked with BioEclipse to complete IND filing and prepare for Phase 1 clinical trial.
  • Tiberend Strategic Advisors, Inc.coreStrategic or Co-development PartnerInvestor relations and media relations firm serving as contact for BioEclipse press inquiries. Provides communications support for corporate announcements.
  • Mahmoud MahmoudiancoreOthersAppointed to BioEclipse Board of Directors in January 2022. Brings 30+ years of biopharma experience from Sumitomo Dainippon Pharma Oncology, Merck, and GlaxoSmithKline. Led $70M in capital to build academic and venture hubs at Sumitomo Oncology.
  • Danforth AdvisorscoreImplementation/ SI/ Consulting PartnerManaging Director Stephen Ghiglieri serves as interim CFO for BioEclipse. Provides CFO services to life sciences companies.
  • Johnson & Johnson Innovation - JLABScoreStrategic or Co-development PartnerBioEclipse was resident company at JLABS in South San Francisco from August 2017 to February 2020. Premier life science incubator program that provided expertise, connections, and team energy to help company grow to clinical-stage.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

BioEclipse Therapeutics competitors and assessment

Company assessment

Emerging players

  • Targovax: Clinical-stage immuno-oncology company developing oncolytic virus (ONCOS-102) for solid tumors. Shares BioEclipse's oncolytic virus approach but is at earlier/mid clinical stage.

Direct peers

  • Replimune: Clinical-stage oncology company developing a portfolio of oncolytic virus therapies (RP1, RP2, RP3) for solid tumors. Shares BioEclipse's oncolytic virus mechanistic approach but is at later clinical stage.
  • Turnstone Biologics: Clinical-stage biotech developing oncolytic virus immunotherapies combined with cell therapy for solid tumors—directly analogous mechanism to BioEclipse's CRX100/CRX200 platform and the most head-to-head comparable peer.
  • Celyad Oncology: Clinical-stage cell therapy company developing allogeneic CAR-T and NK cell therapies for solid tumors. Overlaps with BioEclipse on allogeneic cell therapy positioning for solid tumor indications.
  • Adaptimmune Therapeutics: Cell therapy company developing engineered TCR-T therapies for solid tumors, with Tecelra FDA-approved for synovial sarcoma. Direct competitor in the cell therapy for solid tumors category.
  • Iovance Biotherapeutics: Leader in tumor-infiltrating lymphocyte (TIL) cell therapy for solid tumors, including the FDA-approved Lifileucel. Competes directly with BioEclipse in autologous cell therapy for refractory solid tumors.
  • Lokon Pharma: Clinical-stage gene therapy and oncolytic virus company developing combination approaches for solid tumors, including cell therapy + oncolytic virus strategies that overlap with BioEclipse's platform.
  • Vyriad: Clinical-stage biotech developing oncolytic virus platforms (e.g., Voyager-V1) for solid tumor treatment. Directly comparable viral immunotherapy mechanism to BioEclipse's vaccinia virus component.

Broad incumbents

  • Fate Therapeutics: Clinical-stage cell therapy company developing off-the-shelf, iPSC-derived NK and T-cell therapies for cancer. Comparable to BioEclipse's CRX200 allogeneic, off-the-shelf positioning with broader pipeline scale.
  • Allogene Therapeutics: Leading allogeneic CAR-T developer with substantially greater capital and clinical pipeline. Comparable on allogeneic cell therapy platform positioning but focused primarily on hematologic malignancies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

BioEclipse Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioEclipse Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

BioEclipse Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioEclipse Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioEclipse Therapeutics

What does BioEclipse Therapeutics do?

BioEclipse Therapeutics is a clinical-stage biopharmaceutical company that develops first-in-class, multi-mechanistic immuno-oncology therapeutics combining cytokine-induced killer (CIK) cells with an oncolytic virus to treat solid tumors. Its lead candidates are CRX100 (autologous, currently in Phase 1b clinical trials) and CRX200 (allogeneic, IND-ready), built on cell-therapy technology originally licensed from Stanford University.

Is BioEclipse Therapeutics a public or private company?

BioEclipse Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was BioEclipse Therapeutics founded?

BioEclipse Therapeutics was founded in 2006. It employs 1 to 10 people.

Where is BioEclipse Therapeutics based?

BioEclipse Therapeutics is headquartered in Mountain View, United States, in the North America region.

How does BioEclipse Therapeutics make money?

One revenue line is on record: none currently - Pre-revenue clinical stage.

Who are BioEclipse Therapeutics's main competitors?

Targovax is listed as an emerging player. Direct peers are Replimune, Turnstone Biologics, Celyad Oncology, Adaptimmune Therapeutics, Iovance Biotherapeutics, Lokon Pharma and Vyriad. Broad incumbents are Fate Therapeutics and Allogene Therapeutics.

Does BioEclipse Therapeutics have an API?

No public API is recorded for BioEclipse Therapeutics.

What industry is BioEclipse Therapeutics in?

BioEclipse Therapeutics's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous), with a secondary code of HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioeclipseBioEclipse Therapeutics™ Awarded Almost $8 Million Grant by California Institute for Regenerative Medicine (CIRM) to Fund Ongoing Phase 1 CRX100 Cancer Immunotherapy Clinical TrialBioEclipse Therapeutics received a nearly $8 million grant from the California Institute for Regenerative Medicine to fund its ongoing Phase 1 clinical trial of CRX100, an immunotherapy for advanced solid tumors. The funding supports the evaluation of safety and tolerability for this first-in-class treatment that combines oncolytic viruses with cytokine-induced killer cells. This financial support validates the company's technology as it continues development in patients resistant to standard care.BioSpaceBioEclipse Therapeutics™ Awarded Almost $8 Million Grant by California Institute for Regenerative Medicine (CIRM) to Fund Ongoing Phase 1 CRX100 Cancer Immunotherapy Clinical TrialBioEclipse Therapeutics has been awarded a nearly $8 million grant from the California Institute for Regenerative Medicine (CIRM) to fund its ongoing Phase 1 clinical trial of CRX100, an immunotherapy for advanced solid tumors. The funding supports the evaluation of this first-in-class treatment, which combines oncolytic viruses with cytokine-induced killer cells, across sites in California and Arizona. This financial support validates BioEclipse's technology as it continues development for patients with chemotherapy-resistant cancers.BenzingaBioEclipse Therapeutics™ Awarded Almost $8 Million Grant by California Institute for Regenerative MedicinBioEclipse Therapeutics has been awarded a nearly $8 million grant from the California Institute for Regenerative Medicine to support its Phase 1 clinical study of CRX100 in patients with advanced solid tumors. This funding validates the company's proprietary platform combining oncolytic viruses with cytokine-induced killer cells for treating chemotherapy-resistant cancers. The clinical trial is being conducted at multiple locations including Stanford University, HonorHealth Research Institute, and UC San Diego.PR NewswireBioEclipse Therapeutics™ Awarded Almost $8 Million Grant by California Institute for Regenerative Medicine (CIRM) to Fund Ongoing Phase 1 CRX100 Cancer Immunotherapy Clinical TrialBioEclipse Therapeutics has been awarded a nearly $8 million grant from the California Institute for Regenerative Medicine to fund its ongoing Phase 1 clinical trial of CRX100, an immunotherapy for advanced solid tumors. The funding supports the evaluation of this first-in-class treatment in patients with chemotherapy-resistant cancers at sites including Stanford University and UC San Diego. This financial support validates BioEclipse's technology and aids its development efforts.innovation.ca.govStem Cell Agency Invests in Therapy Using Killer Cells to Target Colorectal, Breast and Ovarian Cancers – CIRMThe California Institute for Regenerative Medicine (CIRM) approved a nearly $8 million investment in BioEclipse Therapeutics Inc. to develop a therapy that uses immune cells to target hard-to-treat tumors, including colorectal, breast, and ovarian cancers. This marks the 78th clinical trial funded by CIRM, aiming to address significant unmet medical needs for chemotherapy-resistant cancers. Additionally, CIRM approved over $18 million for four other regenerative medicine projects.BioSpaceBioEclipse Therapeutics Appoints New Board Member and Names Interim CFOBioEclipse Therapeutics appointed Dr. Mahmoudian to its Board of Directors and named Stephen Ghiglieri as interim Chief Financial Officer. These leadership changes occur as the company evaluates Phase 1 trial results for its lead drug candidate, CRX100, in treating advanced solid tumors.PR NewswireBioEclipse Therapeutics Appoints New Board Member and Names Interim CFOBioEclipse Therapeutics announced the appointment of Mahmoud Mahmoudian, Ph.D., to its Board of Directors and Stephen Ghiglieri as interim Chief Financial Officer. Both appointments come as the company evaluates results from a Phase 1 dose-escalation trial investigating its lead drug candidate CRX100, an immunotherapy combining cytokine-induced killer cells with an oncolytic virus for advanced solid tumors. Dr. Mahmoudian joins from Sumitomo Oncology where he led oncology external innovation and venture investments.PR NewswireBioEclipse Therapeutics™ to Present at Virtual H.C. Wainwright 23rd Annual Global Healthcare ConferenceBioEclipse Therapeutics announced that its Founder and CEO, Pamela Reilly Contag, will present the company's proprietary NKT/oncolytic virus technology platform at the H.C. Wainwright 23rd Annual Global Healthcare Conference in September 2021. The presentation aims to highlight the company's multi-modal therapy approach for treating refractory solid tumors, specifically focusing on its Phase 1 clinical candidate CRX100. BioEclipse is also hosting one-on-one meetings with investors and industry executives during the event.PR NewswireBioEclipse Therapeutics™ to Present at the Spring 2021 Virtual Oncology Investor ConferenceBioEclipse Therapeutics announced that CEO Pam Contag will present at the Spring 2021 Virtual Oncology Investor Conference, providing an overview of the company's business and clinical programs. The company has initiated an open-label Phase 1 dose-escalation study to evaluate its lead drug candidate CRX100 in advanced solid tumors, including triple-negative breast cancer, colorectal cancer, and several other tumor types. CRX100 is a first-in-class, intravenously delivered targeted immunotherapy developed using a proprietary platform combining immune cells and an oncolytic virus.PR NewswireBioEclipse Therapeutics Announces First Patient Dosed in Phase 1 Dose-Escalation Clinical Trial of CRX100 in Refractory Solid TumorsBioEclipse Therapeutics announced the first patient has been dosed in its Phase 1 dose-escalation clinical trial of CRX100, an intravenously delivered immunotherapy combining cytokine-induced killer cells with an oncolytic virus, at HonorHealth Research Institute in Scottsdale, Arizona. The trial will enroll up to 24 participants aged 18 and older across six refractory solid tumor indications, including triple-negative breast cancer, colorectal cancer, and gastric cancer, with secondary endpoints evaluating tumor progression and immune response. The company expects to report top-line data later in 2021, with C3 Research Associates providing clinical trial management and monitoring support.